Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI

  • New results from Medivir’s Phase 1b / 2a open label trial of fostrox + Lenvima® show great promise treating second-line hepatocellular carcinoma (HCC) patients, an extremely hard to treat population
  • Fostrox + Lenvima® achieved a 24% overall response rate (ORR) and estimated median time to progression (TTP) of 10.8 months1 (4.1 – NE) – with one patient still on treatment after 22 months
  • Results come despite very poor prognosis for most second-line HCC patients today, with just 5 – 10% responding to current standard of care treatment, and a typical TTP of only 3 – 4 months
  • Medivir’s fostrox (fostroxacitabine bralpamide) is an orally-administered, liver-targeted inhibitor of DNA replication. The mechanism is different to existing first-line HCC treatments, delivering its cell-killing compound selectively to tumor cells while minimizing harm to healthy cells

Read more…